Trial Outcomes & Findings for Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease (NCT NCT03301272)

NCT ID: NCT03301272

Last Updated: 2020-08-17

Results Overview

The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III's tremor subscore (3.17). The subscale has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse tremor/motor function. Larger differences will infer greater effect size for the intervention. Score drops over time imply improvement in tremor/motor function.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

16 participants

Primary outcome timeframe

Prior to onabotulinumtoxinA injection and at 30 days after injection

Results posted on

2020-08-17

Participant Flow

Participant milestones

Participant milestones
Measure
OnabotulinumtoxinA Injection, Then Placebo
Participants first receive OnabotulinumtoxinA Injection and following a 3-month washout, they receive Placebo OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Placebo, Then OnabotulinumtoxinA Injection
Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection. OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
First Intervention (30 Days)
STARTED
7
9
First Intervention (30 Days)
COMPLETED
7
9
First Intervention (30 Days)
NOT COMPLETED
0
0
Washout (90 Days From 1st Intervention)
STARTED
7
9
Washout (90 Days From 1st Intervention)
COMPLETED
7
9
Washout (90 Days From 1st Intervention)
NOT COMPLETED
0
0
Second Intervention (30 Days)
STARTED
7
9
Second Intervention (30 Days)
COMPLETED
7
9
Second Intervention (30 Days)
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
OnabotulinumtoxinA Injection, Then Placebo
n=7 Participants
Participants first receive OnabotulinumtoxinA Injection and following a 3-month washout, they receive Placebo OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Placebo, Then OnabotulinumtoxinA Injection
n=9 Participants
Participants first receive placebo injection and following a 3-month washout, they receive OnabotulinumtoxinA Injection. OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Total
n=16 Participants
Total of all reporting groups
Age, Continuous
65.7 years
n=7 Participants
64.7 years
n=9 Participants
65.5 years
n=16 Participants
Sex: Female, Male
Female
2 Participants
n=7 Participants
1 Participants
n=9 Participants
3 Participants
n=16 Participants
Sex: Female, Male
Male
5 Participants
n=7 Participants
8 Participants
n=9 Participants
13 Participants
n=16 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
7 Participants
n=7 Participants
9 Participants
n=9 Participants
16 Participants
n=16 Participants
Chosen Limb for Study
Right Arm
4 Participants
n=7 Participants
5 Participants
n=9 Participants
9 Participants
n=16 Participants
Chosen Limb for Study
Left Arm
3 Participants
n=7 Participants
4 Participants
n=9 Participants
7 Participants
n=16 Participants
Mean Number of Parkinson's Medications Failed Prior to Enrollment
3.29 Failed Medications
STANDARD_DEVIATION 1.25 • n=7 Participants
3.0 Failed Medications
STANDARD_DEVIATION 1.22 • n=9 Participants
3.13 Failed Medications
STANDARD_DEVIATION 1.20 • n=16 Participants
Levodopa Equivalent Dosing (LED)
98.29 mg
STANDARD_DEVIATION 54.10 • n=7 Participants
162.22 mg
STANDARD_DEVIATION 103.53 • n=9 Participants
134.25 mg
STANDARD_DEVIATION 89.22 • n=16 Participants

PRIMARY outcome

Timeframe: Prior to onabotulinumtoxinA injection and at 30 days after injection

Population: One participant was unavailable to complete assessment during defined window.

The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society. MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used in this study is Part III's tremor subscore (3.17). The subscale has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse tremor/motor function. Larger differences will infer greater effect size for the intervention. Score drops over time imply improvement in tremor/motor function.

Outcome measures

Outcome measures
Measure
OnabotulinumtoxinA Injection
n=16 Participants
Participants receive OnabotulinumtoxinA Injection. OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once
Placebo
n=15 Participants
Participants receive placebo injection. Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Change in the MDS-UPDRS Tremor Subscore
0.25 score on a scale
Interval -0.246 to 0.746
0.27 score on a scale
Interval -0.342 to 0.876

SECONDARY outcome

Timeframe: Prior to onabotulinumtoxinA injection and at 30 days after injection

Population: Two participants were unavailable to complete assessments during defined window.

The Action Research Arm Test (ARAT) is an evaluated measure to assess specific changes in limb function after neurologic sequelae. It assesses a person's ability to handle objects differing in size, weight and shape and therefore can be considered to be an arm-specific measure of activity limitation. The ARAT is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). Performance on each item is rated on a 4-point ordinal scale: 3: Performs test normally 2: Completes test, but takes abnormally long or has great difficulty 1: Performs test partially 0: Can perform no part of test. The maximum score on the ARAT is 57 points (possible range 0 to 57). Higher ARAT scores reflect greater preservation of function in tested arm. Larger differences will infer greater effect sizes for the intervention. Score drops over time imply worsening limb function.

Outcome measures

Outcome measures
Measure
OnabotulinumtoxinA Injection
n=15 Participants
Participants receive OnabotulinumtoxinA Injection. OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once
Placebo
n=15 Participants
Participants receive placebo injection. Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Change in the ARAT Score
53.67 score on a scale
Interval 49.06 to 58.27
55.47 score on a scale
Interval 54.3 to 56.63

SECONDARY outcome

Timeframe: At Visit 1, prior to 1st injection through Visit 4, 30 days after last injection

MDS-UPDRS retains the four-scale structure with a reorganization of the various subscales. The subscale used is Part III's tremor subscore 3.17. The subscale has a 0-4 rating: (0=no tremor, 1=\<1cm, 2=1-3 cm, 3=3-10 cm, 4=\>10cm). Higher scores reflect worse tremor amplitude. Larger differences infer greater effect size. The Px1 is a novel, external measuring device using motion-capture technology to determine the frequency, direction and amplitude of movement between hand joints. Movement is captured without ever applying direct pressure on the limb. Output includes tremor frequency in Hz and distance traveled by a hand joint as compared to other joints on the hand in cm. The largest tremor amplitude measured by Px1 was acquired 3x/visit, values averaged then compared with the amplitude range corresponding to MDS-UPDRS tremor subscore. This process was repeated for all subjects for Visits 1-4 comparing all values using Spearman correlation coefficient.

Outcome measures

Outcome measures
Measure
OnabotulinumtoxinA Injection
n=16 Participants
Participants receive OnabotulinumtoxinA Injection. OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once
Placebo
n=16 Participants
Participants receive placebo injection. Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Correlation Between MDS-UPDRS Tremor Subscore and Px1 Tremor Amplitude
0.6225 Spearman Correlation Coefficient
0.4354 Spearman Correlation Coefficient

SECONDARY outcome

Timeframe: Prior to onabotulinumtoxinA injection and at 30 days after injection

Population: Given that the Px1 tool was simultaneously undergoing validation during the trial, using the tool to determine the differences in tremor amplitude was deemed inappropriate.

The Px1 is a novel, external measuring device which uses motion-capture technology to determine the frequency, direction, and amplitude of movement between joints within the hand. Oscillatory movement is captured using a camera system and without ever applying any direct pressure upon the limb. Output includes tremor frequency in (Hertz Hz), and distance traveled by a hand joint as compared to other joints on the hand in centimeters (cm)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Prior to onabotulinumtoxinA injection and at 30 days after injection

Population: Given that the Px1 tool was simultaneously undergoing validation during the trial, using the tool to determine the differences in tremor frequency was deemed inappropriate.

The Px1 is a novel, external measuring device which uses motion-capture technology to determine the frequency, direction, and amplitude of movement between joints within the hand. Oscillatory movement is captured using a camera system and without ever applying any direct pressure upon the limb. Output includes tremor frequency in (Hertz Hz), and distance traveled by a hand joint as compared to other joints on the hand in centimeters (cm)

Outcome measures

Outcome data not reported

Adverse Events

Onabotulinumtoxin A Injection

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Onabotulinumtoxin A Injection
n=16 participants at risk
Participants receive Onabotulinumtoxin A Injection. OnabotulinumtoxinA Injection: Reconstituted 10 units/0.1 mL. Administered intramuscular once
Placebo
n=16 participants at risk
Participants receive placebo injection. Placebo: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Musculoskeletal and connective tissue disorders
Weakness of Injected Limb
31.2%
5/16 • Number of events 5 • Adverse events were included starting with the Screening Visit up to and including Visit 5, a total of approximately 150 days.
12.5%
2/16 • Number of events 2 • Adverse events were included starting with the Screening Visit up to and including Visit 5, a total of approximately 150 days.
Injury, poisoning and procedural complications
Pain of Injected Limb
6.2%
1/16 • Number of events 1 • Adverse events were included starting with the Screening Visit up to and including Visit 5, a total of approximately 150 days.
0.00%
0/16 • Adverse events were included starting with the Screening Visit up to and including Visit 5, a total of approximately 150 days.

Additional Information

Daniel Roque, MD

University of North Carolina at Chapel Hill

Phone: 919-966-8178

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place